<?xml version="1.0" encoding="utf-8"?> 

<rss version="2.0"> 

<channel>

<title>LexisNexis&#174; Mealey's&#8482; Emerging Drugs &amp; Devices Legal News</title>

<link>http://www.lexisnexis.com/mealeys/news.aspx</link>

<description>Headline Emerging Drugs &amp; Devices Legal News from LexisNexis&#174;</description>

<language>en-us</language>

<image>

<title>LexisNexis&#174; Headline Emerging Drugs &amp; Devices Legal News</title>

<url>http://www.lexisnexis.com/mealeys/images/lexismealeyslogo.gif</url>

<width>130</width> 
  
<height>29</height>

<link>http://www.lexisnexis.com/mealeys/news.aspx</link>

</image> 

<copyright>Copyright 2009</copyright>

<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Mont. Jury Awards $3.2M In 1st Zometa Jaw Injury Case To Go To Verdict</title>
<description>
<![CDATA[MISSOULA, Mont. - In the first bisphosphonate case to go to verdict, a Montana state court jury on Oct. 21 awarded a plaintiff $3.2 million after finding that Novartis Pharmaceuticals Corp. was negligent in failing to warn her doctors of the risks of its Zometa bone-loss prevention drug and causing her osteonecrosis of the jaw (ONJ) (Peggy L. Stevens v. Novartis Pharmaceuticals Corporation, No. DV-08-100, Mont. Dist., 4th Dist., Missoula Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>British Citizen's Fosamax Case Dismissed From MDL Court On Forum Non Conveniens</title>
<description>
<![CDATA[NEW YORK - The judge overseeing the Fosamax multidistrict litigation on Oct. 21 granted Merck &amp; Co. Inc.'s motion to dismiss a British plaintiff's complaint on the basis of forum non conveniens provided that Merck agrees to be sued in a British court, to waive any statute of limitations defense and to make necessary witnesses available (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, No. 06-md-1789, Barbara Anne Miller v. Merck &amp; Co. Inc., No. 06-5087, S.D. N.Y.; 2009 U.S. Dist. LEXIS 110831). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$7M Fla. Accutane Verdict Reversed By Appeals Court On Learned Intermediary</title>
<description>
<![CDATA[TALLAHASSEE, Fla. - A Florida appeals court panel on Oct. 27 reversed a $7 million Accutane inflammatory bowel disease (IBD) verdict, finding that the plaintiff had not proven failure to warn and causation and that his claim was barred by the learned intermediary doctrine (Hoffman-La Roche Inc., et al. v. Adam W. Mason, No. 1D08-2023, Fla. App., 1st Dist.; 2009 Fla. App. LEXIS 15997; See 10/18/07, Page 6). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Roche Wants Fla. Ruling Applied Post-Verdict To N.J. Accutane Cases</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - Accutane defendant Hoffman-La Roche Inc. lost no time in telling New Jersey's Accutane judge that she should apply an Oct. 27 Florida appeals court ruling to three New Jersey cases that resulted in a $12.9 million verdict (In Re: Accutane Litigation, No. 271 MT, Kelly Mace v. Hoffman-La Roche Inc., No. ATL-L-199-05 MT, Lance Sager v. Hoffman-La Roche Inc., No. ATL-L-197-05 MT, Jordan Speisman v. Hoffman-La Roche Inc., No. ATL-L-196-05 MT, N.J. Super., Atlantic Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Accutane MDL Plaintiffs Want New Evidence, Consultant Role Reconsidered By Court</title>
<description>
<![CDATA[TAMPA, Fla. - Plaintiffs in the Accutane multidistrict litigation on Oct. 13 asked the court to consider new evidence that it says supports the theory of an expert the court recently rejected (In Re: Accutane Products Liability, MDL Docket No. 1626, No. 04-md-2523, M.D. Fla., Tampa Div.; See 8/20/09, Page 14). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Roche: Poster Abstract Is Unreliable Evidence In Accutane Post-Trial Motion</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - An abstract presented as a poster at a medical conference should be considered hearsay and not scientific evidence, Hoffman-La Roche Inc. told the New Jersey Accutane court on Oct. 16 (In Re: Accutane Litigation, No. 271 MT, Kelly Mace v. Hoffman-La Roche Inc., No. ATL-L-199-05 MT, Lance Sager v. Hoffman-La Roche Inc., No. ATL-L-197-05 MT, Jordan Speisman v. Hoffman-La Roche Inc., No. ATL-L-196-05 MT, N.J. Super., Atlantic Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Jury Awards Punitive Damages In Pa. Prempro Case, But Judge Seals Amount</title>
<description>
<![CDATA[PHILADELPHIA - A Pennsylvania state court jury on Oct. 26 ordered Prempro maker Wyeth Inc. to pay punitive damages to an Illinois woman who claims that her use of the hormone replacement therapy caused her to develop breast cancer, but the judge presiding over hormone replacement therapy mass tort proceedings ordered the amount sealed until the conclusion of a similar case in the same court (Connie Barton v. Wyeth Pharmaceuticals Inc., Case No. 040406301, Pa. Comm. Pls., Philadelphia Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Fla. Federal Judge: Levine Applies Fully To Generic Drug Makers</title>
<description>
<![CDATA[TALLAHASSEE, Fla. - A Florida federal judge on Oct. 15 denied a motion for summary judgment in a generic Adderall case, finding that a U.S. Supreme Court ruling allowing brand-name drug makers to strengthen drug warning labels fully applies to generic manufacturers (Jane R. Munroe, et al. v. Barr Laboratories, Inc., No. 07-395, N.D. Fla., Tallahassee Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>South Carolina Zyprexa Case Settles For $45M, Restrictions On Off-Label Marketing</title>
<description>
<![CDATA[SPARTANBURG, S.C. - Eli Lilly and Co. settled South Carolina's state court Zyprexa off-label lawsuit for $45 million, state Attorney General Henry McMaster announced Oct. 23 (State of South Carolina, ex rel. Henry McMaster v. Eli Lilly and Company, No. 2007-CP-42-1855, S.C. Comm. Pls., 7th Jud. Cir.; See 10/15/09, Page 18). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 10%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>10th Circuit Affirms Penalty Against TMJ Maker For Not Reporting Adverse Events</title>
<description>
<![CDATA[DENVER - A panel of the 10th Circuit U.S. Court of Appeals on Oct. 27 affirmed a $170,000 penalty against the maker of temporomandibular joint (TMJ) implants and its president for knowingly failing to report adverse events to the Food and Drug Administration (TMJ Implants, Inc., et al. v. United States Department of Health and Human Services, No. 08-9539, 10th Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 10 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 11%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>NuvaRing MDL Judge Strikes Filing Of Master Complaint</title>
<description>
<![CDATA[ST. LOUIS - The federal judge presiding over the NuvaRing products liability multidistrict litigation on Oct. 23 decided to strike the master complaint from the docket because he did not expect the manufacturers of the contraceptive to seek dismissal of the complaint under Federal Rule of Civil Procedure 12(b) or appeal his ruling denying the motion (In re: NuvaRing Products Liability Litigation, MDL No. 1964, Case No. 08-md-1964, E.D. Mo.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 11 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 12%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$110 Million Settlement In Toxic Vitamin Solution Class Preliminarily Approved</title>
<description>
<![CDATA[WICHITA FALLS, Texas - A federal judge in Texas on Oct. 10 preliminarily approved a $110 million settlement involving claims that a vitamin solution for infants was unreasonably dangerous (Victoria Klein, et al. v. O'Neal Inc., et al. v. Federal Insurance Co., et al., No. 7:03-cv-102, N.D. Texas). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 12 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 13%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Medtronic Sprint Fidelis State Court Litigation Ruled Preempted Under Riegel</title>
<description>
<![CDATA[MINNEAPOLIS - A Minnesota state court judge held Oct. 20 that the claims of nine representative plaintiffs in that state's consolidated Medtronic Inc. Sprint Fidelis implantable defibrillator leads litigation are preempted by federal law (In Re: Medtronic Sprint Fidelis Lead Products State Court Litigation, No. 27-CV-07-22446, Minn. Dist., Hennepin Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 13 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 14%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>7th Circuit: No Error In District Court Dismissal Of Guidant Securities Class</title>
<description>
<![CDATA[CHICAGO - A district court did not err in dismissing without prejudice a putative investor class alleging that Guidant Corp. misrepresented the safety of its Ventak implantable cardioverter defibrillator (ICD) products and a pending merger with Johnson &amp; Johnson (J&amp;J), a Seventh Circuit U.S. Court of Appeals panel ruled Oct. 21 (David Fannon, et al. v. Guidant Corp., et al., No. 08-2429, 7th Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 14 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 15%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Fraud-On-FDA Not Prerequisite To N.J. Punitive Damage Claim In Elidel Cancer Case</title>
<description>
<![CDATA[CAMDEN, N.J. - Proof of fraud on the Food and Drug Administration in an Elidel cancer case is only a prerequisite to a New Jersey state law punitive damage claim, a federal judge ruled Oct. 19 in remanding the case (Roderick Devine v. Novartis Pharmaceuticals Corporation, et al., No. 08-859, D. N.J.; 2009 U.S. Dist. LEXIS 97555). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 15 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 16%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Pain Pump Preemption Appeal Dismissed When Plaintiff Fails To File Record Excerpts</title>
<description>
<![CDATA[ATLANTA - The 11th Circuit U.S. Court of Appeals on Oct. 21 dismissed a pain pump preemption case for want of prosecution after the plaintiff missed a deadline for filing record excerpts (Linda Wolicki-Gables v. Arrow International, Inc., No. 09-14342, 11th Cir.; See 8/6/09, Page 18). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 16 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 17%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>AstraZeneca Dismissed From Shoulder Pump Case For Failure To Adequately Plead</title>
<description>
<![CDATA[PHOENIX - An Arizona federal judge on Oct. 15 dismissed without prejudice claims against drug manufacturer AstraZeneca Pharmaceuticals LP in a shoulder pain pump case after finding that the plaintiff failed to satisfy pleading requirements (Andrew Gilmore, et al. v. DJO Incorporated, et al., No. 08-1252, D. Ariz.; 2009 U.S. Dist. LEXIS 96690). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 17 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 18%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Summary Judgment Granted After Implant Patient Fails To Show Parallel Claims</title>
<description>
<![CDATA[PHOENIX - A breast implant plaintiff failed to show that her state law tort claims paralleled federal requirements and are thus preempted, an Arizona federal judge said Oct. 14 in granting summary judgment to defendant Allergan USA Inc. (Karen Williams, et al. v. Allergan USA, Inc., et al., No. 09-1160, D. Ariz.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 18 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 19%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Paxil Defect Plaintiff Allowed To Supplement Expert Causation Report</title>
<description>
<![CDATA[TULSA, Okla. - A plaintiff in a Paxil birth defect case can submit a supplemental expert report that expands on her original causation opinion, an Oklahoma federal judge ruled Oct. 26 (Jennifer Hayes, et al. v. SmithKline Beecham Corporation, et al., No. 07-682, N.D. Okla., Tulsa Div.; 2009 U.S. Dist. LEXIS 98499). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 19 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 20%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>W. Va. Public Policy Stops Learned Intermediary In Fentanyl Patch Case</title>
<description>
<![CDATA[CHARLESTON, W.Va. - Mylan Inc. on Oct. 23 asked a West Virginia federal court to reconsider its Oct. 14 order denying dismissal of a fentanyl patch death case on choice of law (Lynn Woodcock, et al. v. Mylan, Inc., et al., No. 09-507, S.D. W.Va., Charleston Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 20 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 21%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Colonoscopy Snare Complaint Remanded On Assurance About Limited Recovery</title>
<description>
<![CDATA[LOUISVILLE, Ky. - A Kentucky federal judge on Oct. 23 remanded a medical device case to state court based on the plaintiff's lawyers' affirmation that he is not seeking an amount in excess of the federal threshold amount of $75,000 (Richard B. Van Etten v. Boston Scientific Corporation, No. 09-442, W.D. Ky., Louisville Div.; 2009 U.S. Dist. LEXIS 99079). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 21 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 22%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Indocin SJS Case Out For Lack Of Experts</title>
<description>
<![CDATA[MEMPHIS, Tenn. - A case in which a plaintiff alleged that he developed Stevens-Johnson syndrome (SJS) from Merck &amp; Co. Inc.'s Indocin rheumatoid arthritis drug was dismissed on summary judgment on Oct. 16 because the plaintiff failed to identify expert witnesses (John Taylor v. Merck &amp; Co. Inc., No. 08-2244, W.D. Tenn., W. Div.; 2009 U.S. Dist. LEXIS 96696). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 22 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 23%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Preemption Gone, Zeneca Argues Pleading Defects In Nexium / Prilosec Suit</title>
<description>
<![CDATA[WILMINGTON, Del. - With its preemption summary judgment taken away, Zeneca Inc. on Sept. 15 asked a Delaware federal judge to dismiss a Nexium/Prilosec economic injury case on failure to plead with specificity (Pennsylvania Employee Benefit Trust Fund, et al. v. Zeneca, Inc., et al., No. 05-75, D. Del.; See 3/19/09, Page 7). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 23 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 24%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$1.2M Rezulin Fee Agreement Affirmed By N.Y. Appeals Court</title>
<description>
<![CDATA[NEW YORK - A New York state appeals court on Oct. 22 unanimously affirmed a $1,261,521 fee-sharing judgment in the state's Rezulin mass tort litigation (In Re: New York Rezulin Products Liability Litigation, William Andrews, et al. v. Pfizer, Inc., Girardi &amp; Keese v. Duffy, Duffy &amp; Burdo, Esq., Nos. 1250, 752000/00, 104463/04, N.Y. Sup. App., 1st Dept.; 2009 N.Y. App. Div. LEXIS 7342). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 24 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 25%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Whistle-Blowers: Judge Set 'Public Disclosure' Bar To Be Overly Broad</title>
<description>
<![CDATA[BOSTON - The federal judge who dismissed allegations that doctors accepted kickbacks from Medtronic Sofamor Danek USA Inc. (MSD) in return for off-label promotion of its bone growth product used a standard for previous "public disclosure" pursuant to the False Claims Act (FCA) so broad as to invite drug companies to inoculate themselves by filing bogus lawsuits, appellees argue in a brief filed Oct. 14 in the First Circuit U.S. Court of Appeals (United States ex rel. Jacqueline Kay Poteet, et al. v. Lawrence G. Lenke, M.D., et al., No. 09-1728, 1st Cir; See 4/2/09, Page 21). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 25 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 26%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Zicam Makers Say FDA Won't Change Position That Sprays Are Injurious Drugs</title>
<description>
<![CDATA[SCOTTSDALE, Ariz. - Zicam maker Matrixx Initiatives Inc. said Oct. 26 that the Food and Drug Administration is unwilling to reverse its position that the company's zinc-based nasal sprays are unapproved new drugs that are linked to patients losing their sense of smell and/or taste. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 26 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 27%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>United States Sides With Merck Investors In Supreme Court</title>
<description>
<![CDATA[WASHINGTON, D.C. - The U.S. Office of the Solicitor General filed an amicus curiae brief in Vioxx derivative litigation on Oct. 26 before the U.S. Supreme Court, supporting a putative class of Vioxx derivative plaintiffs who say that even if they were on "inquiry notice" of potential securities fraud in September 2001, they could not have established the requisite scienter until learning that that Merck &amp; Co. Inc. executives did not believe their own claims of the drug's safety (Merck &amp; Co., Inc., et al. v. Richard Reynolds, et al., No. 08-905, U.S. Sup.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 27 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 28%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$274M Pricing Verdicts Against 3 Major Drug Companies Vacated By Ala. High Court</title>
<description>
<![CDATA[MONTGOMERY, Ala. - The Alabama Supreme Court on Oct. 16 vacated $274 million in two prescription drug average wholesale price verdicts and entered judgment in favor of AstraZeneca LP, Novartis Pharmaceuticals Corp. and GlaxoSmithKline plc (GSK), finding that they did not defraud the state Medicaid program and cause it to pay higher-than-needed reimbursement to health care providers (AstraZeneca LP, et al. v. State of Alabama, Nos. 1071439 and 1071704, SmithKline Beecham Corporation, et al. v. State of Alabama, No. 1071704, and Novartis Pharmaceuticals Corporation v. Alabama, No. 1071759, Ala. Cir., Montgomery Co.; See 3/6/08, Page 26). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 28 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 29%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Kentucky Jury Hits AstraZeneca For $14.7M In Drug Overpricing Suit</title>
<description>
<![CDATA[FRANKFORT, Ky. - A Kentucky Circuit Court jury entered a $14.7 million verdict on Oct. 15 against AstraZeneca for defrauding the Kentucky Medicaid program and state consumers by inflating the average wholesale prices (AWPs) of the company's prescription drugs (Commonwealth of Kentucky v. Alpharma Inc., 2004-ci-1487, Ky. Cir., Franklin Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 29 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 30%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>3 Drug Makers Settle False Claims Lawsuit For $124M</title>
<description>
<![CDATA[WASHINGTON, D.C. - Three drug companies will pay a total of $124 million to settle False Claims Act allegations that they or their subsidiaries underpaid rebates due to the federal government for drugs sold to the Medicaid program, the U.S. justice announced Oct. 20 (Citizens For Consumer Justice, et al. v. Abbott Laboratories, et al., No. 01-12257, D. Mass.; See 9/13/09, Page 32). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 30 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 31%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Court: Baycol User Entitled To Amend UCL Action To Show He Paid Higher Prices</title>
<description>
<![CDATA[LOS ANGELES - A judge erred in denying a man leave to amend his unfair competition law action to specify how he paid higher prices as a result of a drug company's overstating of the benefits and safety of its cholesterol-lowering drug, a California appeals court held Oct. 20 (In re Baycol Cases I and II, No. B204943, Calif. App., 2nd Dist.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 31 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 32%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Objectors To Class Settlement Appeal $70M Fee Award In Drug-Pricing Case</title>
<description>
<![CDATA[BOSTON - After a federal Massachusetts judge approved $70 million in attorney fees following a $350 million settlement in a class action fraudulent drug-pricing case, class members opposing the settlement filed notices of appeal (New England Carpenters Health Benefits Fund, et al. v. First Databank Inc., et al., No. 05-11148, D. Mass.; 2009 U.S. Dist. LEXIS 68419; See 9/3/09, Page 29). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 32 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 33%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Philips Healthcare Voluntarily Recalls Defibrillators For Memory Chip Failure</title>
<description>
<![CDATA[SEATTLE - Philips Healthcare announced Sept. 28 that it is voluntarily recalling 5,400 HeartStart FR2+ automated external defibrillators (AEDs) due to the possibility of a memory chip failure that could render the device inoperable. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 33 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>1st Paxil Birth Defect Trial Ends In $2.5M Verdict In Pennsylvania State Court</title>
<description>
<![CDATA[PHILADELPHIA - The first Paxil birth defect trial ended Oct. 13 with a $2.5 million verdict for a mother who says her use of the antidepressant during pregnancy caused her son's heart defect (Lyam Kilker, et al. v. SmithKline Beecham Corp., No. 070201813, Pa. Comm. Pls., Philadelphia Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Paxil Preemption Appeal 1 Of 1st Tests Of Levine High Court Ruling</title>
<description>
<![CDATA[CHICAGO - In one of the first tests of the U.S. Supreme Court's drug preemption ruling in Wyeth v. Diana Levine (No. 06-1249, U.S. Sup.; 2009 U.S. LEXIS 1774; See 3/5/09, Page 5), a federal appeals panel heard arguments on Oct. 5 on whether the Food and Drug Administration considered and rejected a suicide warning for Paxil, preempting the claim of parents whose daughter killed herself two days after taking the antidepressant (Bonnie J. Mason, et al. v. SmithKline Beecham Corporation, et al., No. 08-2265, 7th Cir.; See 5/1/08, Page 6). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>New Hampshire Federal Judge Finds No Preemption Of Generic Drug Liability</title>
<description>
<![CDATA[CONCORD, N.H. - A New Hampshire federal judge on Sept. 30 denied preemption summary judgment in a generic drug injury case, ruling that the federal law designed to speed the introduction of generic drugs does not bar manufacturers from adding warnings as risks emerge (Karen L. Bartlett, et al. v. Mutual Pharmaceutical Company, Inc., et al., No. 08-358, D. N.H.; 2009 U.S. Dist. LEXIS 90528). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Levine To Get Another Test In Generic Liability Appeal In 8th Circuit On Oct. 20</title>
<description>
<![CDATA[ST. LOUIS - The U.S. Supreme Court's drug preemption ruling in Wyeth v. Diana Levine (No. 06-1249, U.S. Sup.; 2009 U.S. LEXIS 1774; See 3/5/09, Page 5) will get another test on Oct. 20 when the Eighth Circuit U.S. Court of Appeals hears arguments on whether tardive dyskinesia claims involving Reglan and generic metoclopramide are preempted by federal law (Gladys Mensing v. Wyeth, Inc., et al., No. 08-3850, 8th Cir.; See 6/19/08, Page 5). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>3rd Circuit Affirms $567M Fen-Phen Attorney Fee Award</title>
<description>
<![CDATA[PHILADELPHIA - A panel of the Third Circuit U.S. Court of Appeals on Oct. 8 affirmed a $567 million common benefit fee to attorneys who prosecuted federal fen-phen cases against Wyeth and achieved a multi-billion class settlement for injured plaintiffs (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Product Liability Litigation, Randy Hague, et al., appellants, No. 08-2363, Law Firms of Freedland, Farmer, Russo, Behren &amp; Sheller, et al. appellants, No. 08-2387, 3rd Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Federal Panel Assigns Hydroxycut Litigation To California District Court</title>
<description>
<![CDATA[WASHINGTON, D.C. - Federal cases involving Iovate Health Sciences USA Inc.'s weight-loss product Hydroxycut, withdrawn from the market amid concerns about liver damage, have been consolidated in U.S. District Court for the Southern District of California by an Oct. 6 order of the Judicial Panel on Multidistrict Litigation (In Re: Hydroxycut Marketing and Sales Practices Litigation, MDL No. 2087, S.D. Calif.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Ethicon Wins Verdict In Surgical Stapler Case</title>
<description>
<![CDATA[LITTLE ROCK, Ark. - An Arkansas federal jury on Oct. 7 found that an Ethicon Endo-Surgery stapler was not defective and that the manufacturer did not breach an implied warranty in a case where a plaintiff alleged that the sutures failed in a gastric bypass surgery (Sharon Chism, et al. v. Ethicon Endo-Surgery Inc., et al., No. 08-341, E.D. Ark.; See 9/3/09, Page 14). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Cephalon Off-Label Settlement Not Grounds For Fraud Claims By Third-Party Payers</title>
<description>
<![CDATA[TRENTON, N.J. - Cephalon Inc.'s settlement of off-label marketing claims for its drugs is not a basis for similar class claims by six third-party payers, a New Jersey federal judge ruled Oct. 7 in dismissing their action with prejudice to one of three claims (Central Regional Employees Benefit Fund, et al. v. Cephalon, Inc., et al., No. 09-3418, D. N.J.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Celexa / Lexapro Kickback, Off-Label Qui Tam Suits Settled In Principle</title>
<description>
<![CDATA[BOSTON - Forest Laboratories Inc. on Oct. 1 said it has reached an agreement in principle to settle certain claims involving alleged kickbacks to doctors to prescribe its Celexa and Lexapro antidepressants and marketing them for off-label uses (United States of America, ex rel. Christopher R. Gobble v. Forest Laboratories Inc., et al., No. 03-10395; United States of America, ex rel. Joseph Piacentile v. Forest Laboratories Inc., et al., No. 05-10201, D. Mass.; See 3/5/09, Page 18). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 10%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Allergan Wants Court To Find Off-Label Promotion Rules Are Unconstitutional</title>
<description>
<![CDATA[WASHINGTON, D.C. - Already under federal investigation for the off-label marketing of Botox, manufacturer Allergan Inc. on Oct. 1 asked a federal court to declare that federal regulations barring promotion of off-label uses of drugs are an unconstitutional violation of its First Amendment free speech rights (Allergan, Inc. v. United States of America, et al., No. 09-1879, D. D.C.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 10 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 11%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Lilly To Pay Idaho $13M To Settle State's Claims About Zyprexa Off-Label Sales</title>
<description>
<![CDATA[BOISE, Idaho - Eli Lilly and Co. on Oct. 13 said it will pay Idaho $13 million to settle the state's claims that Lilly's off-label marketing of Zyprexa cost the state money in prescriptions and in treatment for the drug's serious side effects (State of Idaho v. Eli Lilly and Co., No. 09-432, E.D. N.Y.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 11 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 12%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Connecticut Attorney General Settles Zyprexa Off-Label Claims For $21.5M</title>
<description>
<![CDATA[HARTFORD, Conn. - Connecticut has settled its off-label and failure-to-warn claims against Eli Lilly and Co. involving the antipsychotic drug Zyprexa for $25.1 million, Attorney General Richard Blumenthal announced Sept. 29. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 12 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 13%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>S.C. Zyprexa Lawsuit Tentatively Settled</title>
<description>
<![CDATA[SPARTANBURG, S.C. - Eli Lilly and Co. has tentatively settled South Carolina's state court lawsuit alleging improper promotion of Zyprexa, a company spokesperson told Mealey Publications Oct. 8 (State of South Carolina v. Eli Lilly &amp; Co., No. 2007-CP-42-1855, S.C. Cir., Spartanburg, S.C.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 13 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 14%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>IBD Study Co-Author, School Got $500,000 From Defense In Accutane State Cases</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - Makers of Accutane, its generic equivalent isotretinoin and their law firms paid more than $500,000 to a researcher and his university where a study was produced about the drug and inflammatory bowel disease (IBD) and that is now being proffered as evidence in New Jersey's Accutane mass tort court (In Re: Accutane, No. 271; In Re: Isotretinoin Litigation, ATL-L-1321-09, N.J. Super., Atlantic Co.; See 8/6/09, Page 26). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 14 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 15%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>N.J. Accutane Plaintiffs Refute Validity Of Studies Cited By Roche</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - Plaintiffs in three New Jersey Accutane cases say that if the court considers a recent study presented by the defense in support of its post-trial motion for judgment notwithstanding the verdict (JNOV), it should also consider an abstract being presented this month in which the same authors appear to contradict themselves (In Re: Accutane Litigation, No. 271 MT, Kelly Mace v. Hoffman-La Roche Inc., No. ATL-L-199-05 MT, Jordan Speisman v. Hoffman-La Roche Inc., No. ATL-L-196-05, and Lance Sager v. Hoffman-La Roche Inc., No. ATL-L-197-05, N.J. Super., Atlantic Co.; See 8/6/09, Page 26). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 15 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 16%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Judge: Third-Party Payers Lack Standing To Bring Claims For Alleged Lipitor Fraud</title>
<description>
<![CDATA[NEW YORK - A putative nationwide class of third-party payers lacks standing to bring its claims that Pfizer Inc. concealed the side effects and misrepresented the efficacy of its cholesterol drug Lipitor, a federal judge ruled Sept. 30 (Southern Illinois Laborers' and Employers Health and Welfare Fund, et al. v. Pfizer, Inc., No. 08 CV 5175, S.D. N.Y.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 16 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 17%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Actionable Misstatements Adequately Pleaded In Schering- Plough Class, Judge Says</title>
<description>
<![CDATA[NEWARK, N.J. - A New Jersey federal judge on Sept. 2 denied a motion by Schering-Plough Corp. to dismiss a shareholder securities fraud class action brought over alleged misrepresentations made in connection with a clinical trial of the company's cholesterol drug, Vytorin, holding that the plaintiffs have adequately pleaded actionable misstatements, omission and scienter (In Re: Schering-Plough Corp./ENHANCE Securities Litigation, 08-397, D.N.J.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 17 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 18%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Judge Won't Remand 1st Fosamax Case; Merck Seeks JMOL</title>
<description>
<![CDATA[NEW YORK - The judge overseeing the Fosamax multidistrict litigation on Oct. 7 denied a motion by the plaintiff in the first case to go to trial to remand her case rather than retry it after a mistrial (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, No. 06-md-1789, Shirley Boles v. Merck &amp; Co. Inc., No. 06-1789, S.D. N.Y.; See 9/17/09, Page 4). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 18 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 19%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Merck Sales Rep's Affidavit Falls Short In Effort To Block Fosamax Remand</title>
<description>
<![CDATA[NEW YORK - An affidavit from a Merck sales representative failed to keep the judge overseeing the Fosamax multidistrict litigation from remanding a case naming the sales rep to a Florida court on Sept. 28 (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, No. 06-md-1789, Myra Ward v. Merck &amp; Co. Inc., S.D. N.Y.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 19 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 20%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>JPMDL Issues Show Cause For Creation Of Pamidronate MDL</title>
<description>
<![CDATA[WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Oct. 6 issued an order for parties to show cause why lawsuits involving bone loss drugs other than Aredia and Zometa and defendants other than Novartis Pharmaceuticals Corp. should not be centralized in a separate multidistrict litigation (In Re: Pamidronate Products Liability Litigation, MDL Docket No. 2120, JPMDL). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 20 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 21%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Tissue Harvester Sentenced To 8 Years For Faking Suitability Of Body Parts</title>
<description>
<![CDATA[RALEIGH, N.C. - An operator of a body parts harvesting business was sentenced Oct. 6 to eight years in federal prison and ordered to pay $103,967 in restitution for selling human tissue that was unsuitable for use in living patients (United States of America v. Philip Joe Guyett, Jr., No. 09-cr-40, E.D. N.C.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 21 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 22%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Human Tissue MDL Plaintiffs Say Defendants 'Invited' MDL Court To Err</title>
<description>
<![CDATA[PHILADELPHIA - Plaintiffs in the human tissue multidistrict litigation told the Third Circuit U.S. Court of Appeals court on Sept. 17 that defendants maneuvered the trial judge into limiting discovery so he would arrive at partial summary judgment that erroneously dismissed many claims (In Re: Human Tissue Products Liability Litigation, No. 09-1458, 3rd Cir.; See 4/2/09, Page 22). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 22 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 23%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Chantix MDL Created, Assigned To Judge Johnson In Alabama Northern District</title>
<description>
<![CDATA[WASHINGTON, D.C. - Thirty-seven federal lawsuits alleging personal injury from the smoking cessation drug Chantix were centralized Oct. 1 before U.S. Judge Inge P. Johnson of the Northern District of Alabama (In Re: Chantix [Varenicline] Products Liability Litigation, MDL Docket No. 2092, JPMDL; See 7/23/09, Page 20). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 23 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 24%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Zicam Injury, Sales Cases Sent To Judge Martone In Arizona Federal Court</title>
<description>
<![CDATA[WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Oct. 9 centralized 40 federal lawsuits in which patients allege both personal injury and economic injury from Zicam nasal spray over-the-counter cold remedy (In Re: Zicam Cold Remedy Marketing and Sales Practices Litigation, MDL Docket No. 2096, JPMDL; See 8/20/09, Page 28). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 24 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 25%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>JPMDL Centralizes Yaz / Yasmin Cases In Southern District Of Illinois</title>
<description>
<![CDATA[WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Oct.1 created a multidistrict litigation for federal lawsuits involving injuries allegedly caused by the use of Yaz and Yasmin in the U.S. District Court for the Southern District of Illinois before Judge David Herndon (In re: Yaz/Yasmin Products Liability Litigation, MDL No. 2100, JPMDL; See 8/6/09, Page 23). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 25 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 26%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>2 Union Health Funds Say Bayer Unlawfully Marketed Yaz To Increase Sales</title>
<description>
<![CDATA[PHILADELPHIA - Two health funds for Philadelphia workers on Oct. 5 filed a class action suit in federal court against the makers of Yaz, alleging that the companies fraudulently and unlawfully marketed the oral contraceptive by overstating its safety and efficacy to increase sales (Philadelphia Firefighters Union Local No. 22 Health and Welfare Fund, et al. v. Bayer Healthcare Pharmaceuticals Inc., et al., No. 09-cv-4567, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 26 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 27%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Plaintiffs Defend Right To Tell Treating Doctors About Pfizer's Off-Label Plea</title>
<description>
<![CDATA[BOSTON - Lawyers for a plaintiff in a Neurontin suicide case say they are within their rights to tell a treating physician that defendant Pfizer Inc. and its predecessor companies pleaded guilty to off-label marketing of Neurontin (In Re: Neurontin Marketing, Sales Practices, and Products Liability Litigation, MDL Docket No. 1629, No. 04-10981, Linda B. Scherer, et al. v. Pfizer, Inc., No. 07-11428, D. Mass.; See 10/1/09, Page 20). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 27 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 28%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Ex-Biopure Exec Gets 36 Months In Jail For Faking Terminal Cancer</title>
<description>
<![CDATA[BOSTON - A former senior vice president for Biopure Corp. was sentenced Oct. 6 to 36 months in prison and fined $50,000 for faking terminal cancer to avoid a securities investigation involving the company's Hemopure blood substitute (United States of America v. Howard P. Richman, No. 08-cr-10282, D. Mass.; See 3/19/09, Page 24). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 28 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 29%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>3rd Circuit Upholds Judgment Against Investor Who Alleged Clinical Trial Fraud</title>
<description>
<![CDATA[PHILADELPHIA - An investor who alleges that a clinical researcher fraudulently lured him to invest in a manufacturer of laser vision correction devices cannot bring his common law fraud claims under a fraud on the market theory, a panel of the Third Circuit U.S. Court of Appeals ruled Sept. 24, affirming a district court summary judgment ruling (George Aubrey v. Donald Sanders, M.D., et al., No. 08-4351, 3rd Cir.; 2009 U.S. App. LEXIS 21221). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 29 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 30%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Postmarketing Studies Ordered For Dynamic Pedicle Screw Spinal Fixation Systems</title>
<description>
<![CDATA[ROCKVILLE, Md. - The Food and Drug Administration on Oct. 6 ordered manufacturers of dynamic pedicle screw systems to conduct postmarket studies of the fusion rates, adverse events and revision surgery of the device compared to traditional rigid spinal fixation systems. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 30 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-20 Mealeys Emerg. Drugs Devices 31%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Penumbra Neuron Catheter Recalled After 4 Injuries</title>
<description>
<![CDATA[ROCKVILLE, Md. - Penumbra Inc. and the Food and Drug Administration on Oct. 1 reported the recall of original design Neuron 6F 070 Delivery Catheters after a tendency to kink or flatten was potentially associated with four injuries. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-20 Mealey's Emerg. Drugs Devices 31 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$4.5M Vioxx Verdict Survives Preemption, Parties Learn 5 Months After Dismissal</title>
<description>
<![CDATA[TRENTON, N.J. - In a nearly five-month-old decision not revealed until Sept. 29, the New Jersey Supreme Court dismissed the appeal of a $4.5 million Vioxx verdict in light of the U.S. Supreme Court's preemption ruling in Wyeth v. Diana Levine (No. 06-1249, U.S. Sup.; 2009 U.S. LEXIS 1774; See 3/5/09, Page 5) (John McDarby, et al. v. Merck &amp; Co., Inc., No. A-40, N.J. Sup.; See 6/5/09, Page 4). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>D.C. Circuit Court Affirms Dismissal Of Challenge To Mandatory Anthrax Vaccination</title>
<description>
<![CDATA[WASHINGTON, D.C. - A district court's dismissal of a challenge brought by eight servicemen seeking to enjoin mandatory anthrax vaccinations was upheld Sept. 29 by the District of Columbia U.S. Circuit Court of Appeals, which agreed with a federal judge's finding that the Food and Drug Administration properly found that the vaccine is effective (Thomas Rempfer, et al. v. Joshua M. Sharfstein, M.D., et al., No. 08-5117, D.C. Cir.; See 3/6/08, Page 11). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Ex-InterMune CEO Guilty Of Wire Fraud For Issuing Misleading Press Release</title>
<description>
<![CDATA[SAN FRANCISCO - The former chief executive officer of InterMune Inc. was convicted Sept. 29 of a federal charge of wire fraud in connection with a false and misleading press release about a clinical trial for an off-label use of the company's Actimmune interferon gamma-1b drug (United States of America v. W. Scott Harkonen, No. 08-cr-164, N.D. Calif., San Francisco; See 4/3/09, Page 19). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>MoistureLoc Refund Class Denied A 3rd Time As Unmanageable</title>
<description>
<![CDATA[CHARLESTON, S.C. - The judge overseeing the MoistureLoc multidistrict litigation on Sept. 25 denied for a third time a refund class, noting changing testimony by two class representatives and unmanageable problems in determining class membership (In Re: Bausch &amp; Lomb Contact Lens Solution Products Liability Litigation, MDL Docket No. 1785, No. 2:06-MN-77777-DCN, Azalea Solo, et al. v. Bausch &amp; Lomb Inc., No. 06-2716, D. S.C., Charleston Div.; See 10/18/07, Page 14). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Bausch &amp; Lomb Settles Fusarium Lawsuit For Simplus Contact Solution</title>
<description>
<![CDATA[LAFAYETTE, La. - A federal lawsuit in Louisiana alleging that a contact lens user contracted a Fusarium keratitis eye infection while using Boston-brand Simplus contact lens solution has been settled, according to a Sept. 11 letter to the judge (Robert G. Vidrine, et al. v. Bausch &amp; Lomb, Inc., No. 08-213, W.D. La.; See 8/20/09, Page 22). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>MoistureLoc Complaint</title>
<description>
<![CDATA[Drug / Device: ReNu MoistureLoc contact lens solution Defendant(s): Bausch &amp; Lomb Inc. Case name: Lori Myers, et al. v. Bausch &amp; Lomb, Inc., No. 09-2493 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Preliminary Approval Granted To $41.5 Million Vytorin, Zetia Consumer Class Action</title>
<description>
<![CDATA[NEWARK, N.J. - On Sept. 21, a New Jersey federal judge granted preliminary approval to a $41.5 million settlement of the federal Vytorin/Zetia multidistrict litigation and granted conditional certification to a master class and two subclasses (In Re: Vytorin/Zetia Marketing, Sales Practices and Products Liability Litigation, No. 08-cv-00285, MDL No. 1938, D. N.J.; See 8/6/09, Page 4). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Jury: Prempro Proximately Caused Breast Cancer; Woman Deserves $3.7 Million</title>
<description>
<![CDATA[PHILADELPHIA - A Pennsylvania Court of Common Pleas jury on Sept. 25 found that Prempro was a proximate cause of an Illinois woman's development of breast cancer and that she deserves $3.7 million in compensatory damages (Connie Barton v. Wyeth Pharmaceuticals Inc., Case No. 040406301, Pa. Comm. Pls., Philadelphia Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>1st Circuit Affirms $12.9M Verdict Against AstraZeneca Over Wholesale Pricing</title>
<description>
<![CDATA[BOSTON - The First Circuit U.S. Court of Appeals has affirmed a $12.9 million bench judgment against drug giant AstraZeneca over average wholesale pricing (AWP) of the prostate cancer drug Zoladex, saying Sept. 23 that the plaintiffs' allegations of dishonest pricing were supported by congressional intent (In Re Pharmaceutical Industry Average Wholesale Price Litigation, Blue Cross Blue Shield of Massachusetts, et al., v. AstraZeneca Pharmaceuticals LP, No. 08-1056, 1st Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 10%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>J&amp;J Victory Vacated In Drug Price Litigation For 1 Plaintiff Class</title>
<description>
<![CDATA[BOSTON - A panel of the First Circuit U.S. Court of Appeals on Sept. 18 vacated judgment against a class in the drug average wholesale price multidistrict litigation and remanded it for further consideration (In Re: Pharmaceutical Industry Average Wholesale Price Litigation, Theresa Shepley, et al. v. Johnson &amp; Johnson, et al., No. 08-1002, 1st Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 10 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 11%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Menaflex Approval Under Review Due To FDA Confusion, Political Pressure, FDA Says</title>
<description>
<![CDATA[ROCKVILLE, Md. - The Food and Drug Administration on Sept. 24 said it will review its 510(k) approval of ReGen Biologics Inc.'s Menaflex collagen scaffold surgical mesh after a review found that its December approval occurred amid agency confusion and high-level agency and congressional pressure ("Review of the ReGen Menaflex(R): Departures from Processes, Procedures, and Practices Leave the Basis for a Review Decision in Question," Preliminary Report, September 2009, FDA). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 11 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 12%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>2nd Circuit Won't Certify Limitations Issue In Minocin Injury Case</title>
<description>
<![CDATA[NEW YORK - A panel of the Second Circuit U.S. Court of Appeals on Sept. 29 declined to certify a question about whether a state court dismissal for failure to prosecute a drug liability case triggers New York's six-month tolling of the statute of limitations, in part because of the plaintiffs' "lackadaisical interest" in prosecuting his case (Robert Doyle v. American Home Products Corp., et al., No. 08-2149, 2nd Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 12 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 13%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Consumer Fraud Class Action Remanded To California State Court</title>
<description>
<![CDATA[SAN FRANCISCO - A California federal judge on Sept. 15 remanded to California state court a consumer fraud class action lawsuit accusing a dietary supplement manufacturer of misleading consumers (Joseph Rotenberg, et al. v. Brain Research Labs LLC, et al., No. C-09-2914, N.D. Calif.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 13 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 14%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Expert, FDA Reports Allowed In As Evidence In Ethicon Stapler Case</title>
<description>
<![CDATA[LITTLE ROCK, Ark. - An Arkansas federal judge on Sept. 23 denied a motion to exclude a plaintiff expert in an Ethicon Endo-Surgery stapler case and denied motions to preclude the use of adverse events reported to the federal government (Sharon Chism, et al. v. Ethicon Endo-Surgery, Inc., et al., No. 08-341-WRW, E.D. Ark., W. Div.; See 9/3/09, Page 14). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 14 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 15%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>New York Judge Allows Zoloft Causation Opinion In Defense Of Assault Charges</title>
<description>
<![CDATA[HEMPSTEAD, NY - A New York trial judge on Aug. 21 stood by her earlier decision to allow defense expert testimony in an assault trial that the antidepressant Zoloft can cause excessive aggression in some people (State of New York v. Brandon W. Hampson, No. 2006NA021294, N.Y. Dist., 1st Dist., Nassau Co.; 2009 N.Y. Misc. LEXIS 2182). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 15 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 16%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Roche Wants Withdrawal Of Accutane Excluded From Upcoming N.J. Trial</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - In addition to filing motions that have now become standard in New Jersey's Accutane trial cases, defendant Hoffman-La Roche Inc. on Sept. 25 filed motions in limine to prevent two plaintiffs from making references to the company's recent discontinuation of the acne drug (Kathleen Jordano v. Hoffman-La Roche Inc., No. ATL-L-7162-06 MT, and Daryl Weatherbee v. Hoffman-La Roche Inc., No. ATL-L-3260-04 MT, N.J. Super., Atlantic Co. ; See 9/17/09, Page 16). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 16 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 17%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Roche Agrees To Accutane New Discovery If It's 'Final' And Plaintiffs Share Costs</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - Hoffman-La Roche Inc. says it will agree to additional Accutane discovery if the plaintiffs file no more requests in other courts and to pay the cost of discovery if the new discovery is not admitted into evidence, according to a Sept. 22 filing in the New Jersey mass tort court (In Re: Accutane Litigation, No. 271 MT, N.J. Super., Atlantic Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 17 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 18%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Pfizer Wants Plaintiffs Not To Contact Treating Doctors; Seeks Egilman Sanctions</title>
<description>
<![CDATA[BOSTON - Pfizer Inc. on Sept. 17 asked the Neurontin multidistrict litigation court to restrict plaintiffs from communicating with treating physicians and to sanction Dr. David Egilman (In Re: Neurontin Marketing, Sales Practices, and Products Liability Litigation, MDL Docket No. 1629, No. 04-10981; Linda B. Shearer, et al. v. Pfizer Inc., et al., No. 07-11428, D. Mass.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 18 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 19%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Neurontin MDL Plaintiff Seeks Additional Discovery Of Doctors, Marketing 'Coach'</title>
<description>
<![CDATA[BOSTON - A plaintiff in the Neurontin multidistrict litigation on Sept. 18 moved to compel information disclosure of additional information relating to the off-label marketing of the drug (In Re: Neurontin Marketing, Sales Practices, and Products Liability Litigation, MDL Docket No. 1629, No. 04-10981, D. Mass.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 19 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-19 Mealeys Emerg. Drugs Devices 20%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$15.6M Fee Awarded In Phenylpropanolamine Consolidated Litigation</title>
<description>
<![CDATA[SEATTLE - The federal judge supervising consolidated litigation over the withdrawn diet drug phenylpropanolamine (PPA) awarded $15.6 million in common benefit fees on Sept. 18 to 19 plaintiff law firms (In Re: Phenylpropanolamine [PPA] Products Liability Litigation, MDL No. 1407, W.D. Wash.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-19 Mealey's Emerg. Drugs Devices 20 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>

</channel>

</rss> 

